Incyte Maps Post-JAKAFI Growth as Key Drug Data and 2027 Launch Loom

Incyte logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Incyte is targeting double-digit annual growth after JAKAFI loses exclusivity at the end of 2028, aiming to build its non-JAKAFI business to $3 billion–$4 billion by then. Growth is expected from existing medicines and pipeline launches, including povorcitinib, which the company hopes to launch in early 2027.
  • Near-term pipeline focus includes upcoming data on CALR antibody 989 and plans for a frontline Phase 3 trial in the first half of 2027. Incyte also expects to begin clinical testing of next-generation antibody 798 in early 2027, after preclinical results showed greater potency against non-Type 1 mutations.
  • Incyte expects R&D spending to rise in 2027 as Phase 3 programs advance, while seeking offsets elsewhere. Conversion to JAKAFI XR was about 3% at the end of the third quarter; if the pace continues, the company expects it to reach its projected 10%–30% range by JAKAFI’s exclusivity loss.
  • MarketBeat previews the top five stocks to own by December 1st.

Incyte NASDAQ: INCY is counting on growth from its existing medicines and a pipeline of late-stage treatments to support the company after JAKAFI loses exclusivity at the end of 2028, executives said at the UBS Global Biopharma Conference in London.

President and Global Head of Research and Development Pablo Cagnoni said the company aims to grow its business outside JAKAFI, including OPZELURA, MONJUVI, NIKTIMVO and ZYNYZ, while advancing drugs that could generate pivotal data and launch in 2028, 2029 and beyond. Incyte also hopes to launch povorcitinib in early 2027.

“We’re not solving for the LOE. We’re solving for post-LOE growth,” Cagnoni said, referring to JAKAFI’s loss of exclusivity. The company’s goal is double-digit compound annual growth after that event, he said.

CALR Data and Trial Design

A key near-term update will come at the American Society of Hematology conference, where Incyte plans to present data on its CALR antibody 989 in approximately 40 previously untreated patients with myelofibrosis who are eligible for JAK inhibitors. Patients were randomized to receive 989 alone or with JAKAFI.

Cagnoni said the presentation will include more patients and longer follow-up than the conference abstract. He expects efficacy in the JAK-eligible group to be better than in a previously reported group of patients who were ineligible for JAK inhibitors, although he did not quantify the expected difference.

The company will also examine 989’s effect on anemia and compare the single-agent and combination results as it designs a frontline Phase 3 study, which it plans to start in the first half of 2027. Cagnoni said adding JAKAFI could improve spleen-volume response but might also reduce the anemia improvement provided by 989.

Incyte plans to discuss a proposed composite endpoint for the trial with the U.S. Food and Drug Administration early in the first quarter. The endpoint would measure hemoglobin, platelets, peripheral blood blasts and spleen volume, with patients required to meet all four measures. If regulators do not accept it, Cagnoni said, Incyte would use the established spleen-volume and symptom-response endpoints.

The company also plans to present preclinical data on a next-generation CALR antibody, 798. Cagnoni said the candidate showed 70 times greater potency against non-Type 1 mutations than 989 in preclinical work. Incyte expects to begin clinical testing in early 2027 and, if development proceeds well, start pivotal trials in mid-2028.

Pipeline Spending and JAKAFI Conversion

Cagnoni said Incyte is testing its G12D inhibitor 734 with two chemotherapy regimens in pivotal trials and is pursuing other combinations through collaborations. The company is also seeking a partner to test 734 with a pan-RAS inhibitor, he said.

Executive Vice President and Chief Financial Officer Suky Upadhyay said research and development spending is likely to increase in 2027 as Phase 3 programs advance. He described the spending trajectory as dynamic rather than linear and said the company would seek offsets elsewhere.

Incyte ended the third quarter with about 3% conversion to JAKAFI XR, its extended-release formulation, Upadhyay said. If the trajectory continues, he expects conversion to fall within the company’s projected range of 10% to 30% by JAKAFI’s expiration.

For povorcitinib in hidradenitis suppurativa, Upadhyay said the company expects clarity on the label in the first quarter and anticipates a partial year of uptake in 2027. He estimated first-year sales at 5% to 10% of peak sales.

Upadhyay said Incyte is investing to bring its core business outside JAKAFI to $3 billion to $4 billion by the loss of exclusivity, including by shifting spending from mature brands to product launches. Cagnoni said the company stopped its CDK2 program after weighing a changing competitive landscape, trial complexity and a projected 2032 readout against other uses for the capital.

About Incyte (NASDAQ:INCY)

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Incyte Right Now?

Before you consider Incyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.

While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines